Found: 6
Select item for more details and to access through your institution.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 180, n. 3, p. 635, doi. 10.1007/s10549-020-05575-9
- By:
- Publication type:
- Article
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 179, n. 1, p. 67, doi. 10.1007/s10549-019-05454-y
- By:
- Publication type:
- Article
Lateral hypothalamic proenkephalin neurons drive threat-induced overeating associated with a negative emotional state.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42623-6
- By:
- Publication type:
- Article
Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.660900
- By:
- Publication type:
- Article
Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig.
- Published in:
- Science Translational Medicine, 2024, v. 16, n. 751, p. 1, doi. 10.1126/scitranslmed.adk6152
- By:
- Publication type:
- Article